Verdiva Bio Launched With Record Series A To Advance Weekly Oral GLP-1

 
• By Andrew McConaghie

Investor appetite for obesity-based biotechs shows no sign of waning as UK-based Verdiva Bio launches with a $411m series A and ambitions to develop an oral, weekly GLP-1 product.

Scales obesity
• Source: Shutterstock

More from Scrip

More from Business